Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharms Lu177-PentixaTher to be Presented at ASCO-GU 2025

Company: Pentixapharm Holding AG Date: 2025-02-13 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Corporate | 13 February 2025 14:10

#   

First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025

Pentixapharm Holding AG / Key word(s): Conference  

First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025  

  

13.02.2025 / 14:10 CET/CEST  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**Berlin, Germany, February 13, 2025** – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm’s Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2025) in San Francisco, CA.

The presentation features a case study of a late-stage MIBC patient who was initially treated with three cycles of neoadjuvant combination chemotherapy followed by intravesical administration of Pentixapharm’s radiopharmaceutical that targets the CXCR4 receptor. Imaging with Ga68-PentixaFor PET/CT had revealed intravesical CXCR4 expression prior to therapy, so a subsequent Lu177-PentixaTher instillation was used to target residual tumor cells. Pathological examination after transurethral resection confirmed a complete response, suggesting a potential for bladder preservation.

Instillation therapy in bladder cancer opens the potential for localized treatment with enhanced precision and minimized systemic exposure, thereby reducing the risk of adverse effects.

This early data adds to the growing body of evidence supporting CXCR4 as a therapeutic target across multiple oncology indications. To date, more than 100 patients have been treated with PentixaTher, providing a basis for a Pentixapharm-sponsored clinical development program. In November of last year, a first patient was enrolled in an investigator initiated Phase I/II trial in patients with acute myeloid and lymphoblastic leukemia (AML/ALL) in Nantes, France.  

**Presentation Details:**

-   **Presenter:** Dr. Ralph Wirtz
-   **Session:** Poster Session B
-   **Date:** February 14, 2025
-   **Time:** 11:30 AM – 12:45 PM (PT)
-   **Location:** ASCO-GU 2025, San Francisco, CA

**About Pentixapharm**

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.

**For more information, please contact:**

Pentixapharm Holding AG  

Phillip Eckert, Investor Relations  

[ir@pentixapharm.com](mailto:ir@pentixapharm.com)  

Tel. +49 30 94893232  

[www.pentixapharm.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=3730f3dd85739c22424ce9293b87d320&application_id=2086021&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news)

  

- - -

13.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Pentixapharm Holding AG |
|     | Robert-Rössle-Straße 10 |
|     | 13125 Berlin |
|     | Germany |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2086021 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | EQS News Service |

- - -

2086021  13.02.2025 CET/CEST

![fncls.ssp?fn=show_t_gif&application_id=2086021&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2086021&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.